XBP Europe Awarded a Transformation Project for His Majesty’s Passport Office (HMPO) LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- XBP Europe (“XBP Europe” or the “Company”) (NASDAQ: XBP and XBPEW), today announced that the Company has been selected by His Majesty’s Passport Office (“HMPO”) as its technology and services partner on a nationwide project, which aims to make documents dating back to 1837 digitally available to the General Register Office (“GRO”). This multi-year contract in the UK has an approximate total contract value of $40 million. A duty to the publicThe GRO, part of HMPO, ...
XBP Europe Awarded a Transformation Project for His Majesty’s Passport Office (HMPO) NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- XBP Europe (“XBP Europe” or the “Company”) (NASDAQ: XBP and XBPEW), today announced that the Company has been selected by His Majesty’s Passport Office (“HMPO”) as its technology and services partner on a nationwide project, which aims to make documents dating back to 1837 digitally available to the General Register Office (“GRO”). This multi-year contract in the UK has an approximate total contract value of $40 million. A duty to the publicThe GRO, part of HMPO...
Kayne Anderson Energy Infrastructure Fund Provides Unaudited Balance Sheet Information and Announces Its Net Asset Value and Asset Coverage Ratios at April 30, 2024 HOUSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of April 30, 2024. As of April 30, 2024, the Company’s net assets were $1.9 billion, and its net asset value per shar...
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth Total revenue for Q1 2024 of $63.5 million, including a $12.5 million milestone payment for BRIUMVI launch in first EU country New BRIUMVI prescriptions to the TG hub of over 1,250 for Q1 2024, representing >25% growth quarter over quarter Conference call to be held today, May 1, 2024, at 8:30 AM ET NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Compan...
Axsome Therapeutics Recognizes May as Mental Health Awareness Month NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today is joining the global community of mental health advocates, including Mental Health America, during May’s Mental Health Month to raise awareness of the importance of mental health as a key element of overall health. Axsome is committed to the millions of individuals living with mental health conditions...
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update Conference call to be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET to discuss results for the first quarter of 2024 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-40...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
EQS-News: AMAG Austria Metall AG / Key word(s): Quarter Results AMAG Austria Metall AG: Challenging environment influences quarterly result 24.04.2024 / 07:20 CET/CEST The issuer is solely responsible for the content of this announcement. Ranshofen, April 24, 2024 AMAG Austria Metall AG: Challenging environment influences quarterly result Quarterly performance influenced by lower aluminium price and lower shipment volumes due to partly subdued incoming orders in Q4/2023 Revenue of EUR 335.8 million below the previous year's level due to price and volume factors (Q1/...
EQS-News: AMAG Austria Metall AG / Schlagwort(e): Quartalsergebnis AMAG Austria Metall AG: Herausforderndes Umfeld beeinflusst Quartalsergebnis 24.04.2024 / 07:20 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Ranshofen, 24. April 2024 AMAG Austria Metall AG: Herausforderndes Umfeld beeinflusst Quartalsergebnis Quartalsentwicklung beeinflusst von niedrigerem Aluminiumpreis und geringerer Absatzmenge infolge der teils verhaltenen Auftragseingänge in Q4/2023 Umsatzerlöse mit 335,8 Mio. EUR preis- und mengenbedingt unter dem Vorja...
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. Links to the data presented yesterday are included below. ...
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS). Michael S. Weiss, Chief Executive Officer and Chairman of ...
Exela Technologies, Inc. to Host Fourth Quarter 2023 and Full Year 2023 Financial Results Conference Call IRVING, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Exela Technologies, Inc. (“Exela” or the “Company”) (NASDAQ:XELA, XELAP), a global business process automation (“BPA”) leader, will host a conference call with the financial community to discuss results for the fourth quarter and full year 2023 at 4:30 p.m. ET on April 17, 2024. Hosting the call and reviewing the results will be Par Chadha, Executive Chairman, and Matt Brown, Interim Chief Financial Officer. The conference call will...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.